Ibogaine

Veterans Seek Healing Through Psychedelic Therapy As Seen In New Documentary 'In Waves And War'
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling
Atai Q3 Report: Strong Cash Position, Clinical Pipeline Growth
DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling
Clearmind Medicine Files International Patent For Ibogaine Combination Therapy
Google Co-Founder Sergey Brin Pledges $15M To Psychedelics Research Start-Up

Ibogaine Recent News

Psyched: Psychedelics For Brain Injury, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, $50M For Atai And More
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Zappy Zapolin Hopes To Put Ibogaine Front And Center For Addiction
Known as the "Psychedelic Concierge to The Stars," Zappy Zapolin has teamed up with Universal Ibogaine (TSXV: IBO) to help bring this important substance to the masses. Ibogaine is an African root considered the only legitimate addiction interrupter capable of breaking a heroin, meth, opiate, or alcohol addiction in a single 12-hour session.
This Maine City Moves Unanimously On Decriminalizing Psychedelics: Focus On Public Health
In a groundbreaking move, Portland, Maine unanimously advances a resolution aimed at decriminalizing select psychedelic plants and fungi.
Psychedelics To Treat Addiction? How Substances Like Ibogaine Are Changing The Game
This article was originally published on Microdose and appears here with permission
African Iboga Root Heads To Canadian Company Developing Natural Drugs To Help Treat Addictions
Clinical-stage natural psychedelics company Filament Health Corp. (OTCQB: FLHLF) has completed the first-ever Nagoya Protocol-compliant import of Tabernanthe iboga root from Gabon to the company’s R&D Vancouver facility.
EXCLUSIVE: Ibogaine Therapy Co. Bienstar On Successful Addiction Treatment, Global Market & Future Prospects
The latest episode of Benzinga’s Cannabis Insider with Javier Hasse and Elliot Lane looked at a psychedelic substance that doesn't get much front-page attention yet has remarkable success rates in treating addiction. We're referring to ibogaine.
Psychedelics Update: MDMA Export, 3D Farm, Recovery Center Reopens, Mushroom Extraction & E-Commerce
Health Canada Oks Clinical-Grade MDMA Export To UK Life sciences psychedelics company PharmAla Biotech Holdings Inc. and its manufacturing partners received a Health Canada export permit for no less than 300 grams of proprietary MDMA LaNeo.
Ibogaine To Treat Addiction: 5 Reasons Why It's Safer To Do It In Hospital Settings
By Santiago Federico Richetti via El Planteo
Science Feature: Next-Generation Psychedelics
This article was originally published on Microdose and appears here with permission.
MindMed Reports Promising Results For Non-Hallucinogenic Ibogaine Congener Substance
MindMed Inc. (NASDAQ: MNMD) reported favorable results for one of its proprietary compounds.
Psyched: Atai, MindMed, Enveric and Mydecine Release 2021 Earnings, Bienstar Expands To Brazil & More!
It’s earnings week in the psychedelics space, opening a new window into the financial situations of many companies in the sector.
What Is Iboga And How Does It Compare To Cannabis, Exactly?
This article was originally published on Cannabis.net and appears here with permission. These days, the use of psychedelics and alternative medicine is rapidly growing once again.
5 Psychedelics For Mental Health
This article was originally published on The Bluntness and appears here with permission.
MindMed Successfully Completes Phase 1 Trial Of 18-MC
This article was originally published on Microdose and appears here with permission.
National Institute on Drug Abuse Will Test Ibogaine For Addiction Treatment As Drug Deaths Crest 100,000
The U.S. government has taken a significant step toward tackling the mounting national substance addiction crisis by partnering with neuroscience company Delix Therapeutics to study a non-hallucinogenic version of the psychedelic drug ibogaine.  
Novamind Partners With Bienstar Wellness, Opening Door To Ibogaine Treatment For Addiction Disorders
Novamind Inc. (OTCQB: NVMDF) a mental health company specializing in psychedelic medicine, recently announced a strategic investment and advisory agreement with Bienstar Wellness Corp, an Uruguay-based mental health company, to assist in the expansion of Latin Ameri
New Study Links Psychedelic Use With 55% Decrease In Daily Opioid Use
Psychedelic use may provide a window of opportunity to kick drug addiction, according to a recent study.
California Bill To Decriminalize Psychedelics Moves Forward: Legislation's Sponsor Talks 'Learning Curve,' Why MDMA, LSD Are Included
A bill to decriminalize psychedelic substances in California is quickly moving up the legislative ladder.
Psyched: Inside A Psilocybin Retreat, CA Bill Would Decriminalize Psychedelics, Revive Buys Psilocybin IP
Inside of a Legal Psilocybin Wellness Retreat At Benzinga, we do what we say, and we say what we do. This hands-on mentality allowed me to take a week off to experience a legal psilocybin retreat in Jamaica.
Mind Cure Closes $18M Raise
Mind Cure Health Inc. (CSE: MCUR), a mental health and wellness company working in the psychedelics sector, announced the closing of a CA$23 Million ($18.1 million) offering.
'Psyched': Psychedelics Measure DC Ballot, GreenStar Buys Eleusian, MindMed Wraps Clinical Trial
District of Columbia To Include Psychedelics Decriminalization Measure on November Ballot The District of Columbia will likely become the nation’s second jurisdiction to include a psychedelics decriminalization measure in November.
MindMed Lists On NEO Exchange, Becomes First Psychedelics Company To Go Public
Bruce Linton's 2020 Vision: Free CBD, Cannabis Opportunities In Europe, Legal Psychedelics
;

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga

© 2025 Benzinga | All Rights Reserved